Ravi Jayadevappa, PhD, MS, discusses results from a study that examined the association between hospital competition, quality, and cost of prostate cancer care among Medicare fee-for-service beneficiaries.
Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.
Petros Grivas, MD, PhD, discusses results from a qualitative interview study evaluating the adoption of avelumab first-line maintenance therapy as standard of care for metastatic urothelial cancer in the United States.
Vidit Sharma, MD, discusses results from a cost-effectiveness analysis comparing pembrolizumab with radical cystectomy or salvage intravesical chemotherapy for patients with BCG-unresponsive carcinoma in situ of the bladder.
Daniel Lage, MD, MSc, discusses study findings showing hospitalized patients with advanced genitourinary cancers had significantly greater functional impairment and worse survival compared to those with other cancer types.
Kim Chi, MD, FRCPC, discusses 4-year efficacy and safety results from the phase 3 TITAN trial, which evaluated apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving ADT.